2. UroToday Home
  3. Conference Highlights
  4. AUA 2019
  5. AUA 2019 Press Releases

AUA 2019

Late-Breaking Abstract Showcases One-Year Outcomes of Pivotal MRI-Guided Transurethral Ultraound Ablation of Localized Prostate Tumors

San Francisco, CA (UroToday.com) -- Magnetic-resonance imaging (MRI) is increasing in use in the diagnosis and treatment of prostate cancer. The TACT study, a multi-center trial across institutions in the United States, Canada and Europe, explores the efficacy of MRI-guided transurethral ultrasound ablation technology in men with localized disease and presents one-year outcomes from TACT. The study will be presented publicly at on May 5 during the Plenary: Next Frontier session.
WHEN: Sunday, May 5, 2019, 10:30 a.m. 

WHERE: AUA Press Suite (Field B, Hyatt Regency McCormick Place) 

WHAT: Expert Q&A Opportunity to Discuss the TULSA-PRO Ablation Clinical Trial (TACT) 

WHO: Study author Dr. Scott Eggener, Professor of Surgery and Radiology at the University of Chicago, will share data and take questions from interested members of the press. 

Further Related Content: 
AUA 2019 Annual Meeting Conference Highlights - Starting Soon! May 3, 2019